Esketamine combined with pregabalin on acute postoperative pain in patients undergoing resection of spinal neoplasms: study protocol for a randomized controlled trial.
Acute postoperative pain
Esketamine
Pregabalin
Randomized controlled trial
Spinal neoplasms
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
25 Feb 2023
25 Feb 2023
Historique:
received:
01
05
2022
accepted:
17
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
Perioperative pain management is one of the most challenging issues for patients with spinal neoplasms. Inadequate postoperative analgesia usually leads to severe postsurgical pain, which could cause patients to suffer from many other related complications. Meanwhile, there is no appropriate analgesic strategy for patients with spinal neoplasms. This is a protocol for a randomized double-blind controlled trial to evaluate the effect of esketamine combined with pregabalin on postsurgical pain in spinal surgery. Patients aged 18 to 65 years scheduled for spinal neoplasm resection will be randomly allocated into the combined and control groups in a 1:1 ratio. In the combined group, esketamine will be given during the during the surgery procedure until 48-h postoperative period, and pregabalin will be taken from 2 h before the surgery to 2 weeks postoperatively. The control group will receive normal saline and placebo capsules at the same time points. Both groups received a background analgesic regimen by using patient-controlled intravenous analgesia (containing 100 μg sufentanil and 16 mg ondansetron) until 2 days after surgery. To ensure the accuracy and reliability of this trial, all the researchers and patients will be blinded until the completion of this study. The primary outcome will be the proportion of patients with acute moderate-to-severe postsurgical pain (visual analog scale, VAS ≥ 40, range: 0-100, with 0, no pain; 100, the worst pain) during the 48-h postoperative period. The secondary outcomes will include the maximal VAS scores (when the patients felt the most intense pain over the last 24 h before being interviewed) at 0-2 h, 2-24 h, 24-48 h, and 48-72 h after leaving the operating room and 24 h before discharge; the incidence of acute moderate-to-severe postsurgical pain at each other time point; chronic postsurgical pain assessment; neuropathic pain assessment; and the incidence of drug-related adverse events and other postoperative complications, such as postoperative delirium and postoperative nausea and vomiting (PONV). The aim of this study was to evaluate the effect of esketamine combined with pregabalin on acute postsurgical pain in patients undergoing resection of spinal neoplasms. The safety of this perioperative pain management strategy will also be examined. ClinicalTrials.gov NCT05096468. Registered on October 27, 2021.
Sections du résumé
BACKGROUND
BACKGROUND
Perioperative pain management is one of the most challenging issues for patients with spinal neoplasms. Inadequate postoperative analgesia usually leads to severe postsurgical pain, which could cause patients to suffer from many other related complications. Meanwhile, there is no appropriate analgesic strategy for patients with spinal neoplasms.
METHODS/DESIGN
METHODS
This is a protocol for a randomized double-blind controlled trial to evaluate the effect of esketamine combined with pregabalin on postsurgical pain in spinal surgery. Patients aged 18 to 65 years scheduled for spinal neoplasm resection will be randomly allocated into the combined and control groups in a 1:1 ratio. In the combined group, esketamine will be given during the during the surgery procedure until 48-h postoperative period, and pregabalin will be taken from 2 h before the surgery to 2 weeks postoperatively. The control group will receive normal saline and placebo capsules at the same time points. Both groups received a background analgesic regimen by using patient-controlled intravenous analgesia (containing 100 μg sufentanil and 16 mg ondansetron) until 2 days after surgery. To ensure the accuracy and reliability of this trial, all the researchers and patients will be blinded until the completion of this study. The primary outcome will be the proportion of patients with acute moderate-to-severe postsurgical pain (visual analog scale, VAS ≥ 40, range: 0-100, with 0, no pain; 100, the worst pain) during the 48-h postoperative period. The secondary outcomes will include the maximal VAS scores (when the patients felt the most intense pain over the last 24 h before being interviewed) at 0-2 h, 2-24 h, 24-48 h, and 48-72 h after leaving the operating room and 24 h before discharge; the incidence of acute moderate-to-severe postsurgical pain at each other time point; chronic postsurgical pain assessment; neuropathic pain assessment; and the incidence of drug-related adverse events and other postoperative complications, such as postoperative delirium and postoperative nausea and vomiting (PONV).
DISCUSSION
CONCLUSIONS
The aim of this study was to evaluate the effect of esketamine combined with pregabalin on acute postsurgical pain in patients undergoing resection of spinal neoplasms. The safety of this perioperative pain management strategy will also be examined.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT05096468. Registered on October 27, 2021.
Identifiants
pubmed: 36841794
doi: 10.1186/s13063-023-07178-3
pii: 10.1186/s13063-023-07178-3
pmc: PMC9960454
doi:
Substances chimiques
Pregabalin
55JG375S6M
Esketamine
50LFG02TXD
Analgesics
0
Banques de données
ClinicalTrials.gov
['NCT05096468']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
144Subventions
Organisme : Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support
ID : ZYLX201708; DFL20180502
Organisme : Beijing Municipal Science and Technology Commission
ID : Z19110700660000, Z191100006619067
Informations de copyright
© 2023. The Author(s).
Références
Medicine (Baltimore). 2017 Sep;96(37):e8031
pubmed: 28906391
Anesthesiology. 2019 Jul;131(1):119-131
pubmed: 31149930
Clin J Pain. 2019 Mar;35(3):272-278
pubmed: 30499836
Reg Anesth Pain Med. 2018 Jul;43(5):456-466
pubmed: 29870457
J Pain. 2016 Feb;17(2):131-57
pubmed: 26827847
Cochrane Database Syst Rev. 2019 Jan 23;1:CD007076
pubmed: 30673120
Medicine (Baltimore). 2017 Mar;96(11):e6129
pubmed: 28296725
Cochrane Database Syst Rev. 2013 Jul 24;(7):CD008307
pubmed: 23881791
JAMA Intern Med. 2017 Aug 1;177(8):1146-1153
pubmed: 28586818
Mayo Clin Proc. 2016 Jul;91(7):955-70
pubmed: 27344405
Cochrane Database Syst Rev. 2018 Dec 20;12:CD012033
pubmed: 30570761
J Pain Res. 2017 May 09;10:1071-1078
pubmed: 28533695
Pak J Med Sci. 2015 Jul-Aug;31(4):833-6
pubmed: 26430413
Anesthesiology. 2018 Sep;129(3):590-607
pubmed: 29738328
Anesthesiology. 2020 Aug;133(2):265-279
pubmed: 32667154
J Clin Anesth. 2021 Feb;68:110071
pubmed: 33007645
JAMA Surg. 2018 Apr 1;153(4):303-311
pubmed: 29238824
Psychol Med. 2014 Mar;44(4):697-706
pubmed: 23822897